Hoechst Hurts
Executive Summary
Jurgen Dormann, the chairman of Hoechst AG, has been trying to make the lumbering German conglomerate into a life-sciences racehorse. But the racehorse may have gotten away from him. In February, open revolt broke out within the German R&D group after an announcement that 600 positions were being cut.
You may also be interested in...
Sandoz Looks Ahead To Biosimilar Opportunities
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.
UK/EU Industry ‘Still Working In The Dark’ On Post-Brexit Regulation
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.
Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III
Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.
Need a specific report? 1000+ reports available
Buy Reports